You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: N

    DESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    SBC: GLYCOMIRA, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss from loss of mandibular anchorage Gingivitis and periodontitis are initiated by chronic infection o ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIAAA

    DESCRIPTION provided by applicant Excessive alcohol use is associated with a range of serious and costly health social and economic consequences at the individual and societal level This program of research serves as a venue by which to produce and test an innovative science based and cost effective means to intervene in a private convenient and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Automated 3D quantitative analysis of dendritic spines imaged with light microsco

    SBC: MICROBRIGHTFIELD, LLC            Topic: NIMH

    DESCRIPTION provided by applicant In this Lab to Marketplace proposal we aim to develop the MBF SpineStudio software incorporating the innovative laboratory based NeuronStudio software created at the Mount Sinai School of Medicine Our SpineStudio software will enable automated detection reconstruction and morphological classification of the structural analysis of dendritic spines By creating this ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Low Cost Laser Diagnostic for CD4+ T Cell Counting

    SBC: MBIO DIAGNOSTICS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop and commercialize a simple cell counter for routine enumeration of CD4 cells for management of HIV-infected individuals. HIV-1 mediated CD4 cell destruction is the centralimmunologic feature of HIV-1 infection. Thus, the CD4 count is a critical measurement in initial disease staging, in monitoring antiretroviral t ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A new, rapidly dissolving and thermally stable dry powder Hepatitis-B vaccine

    SBC: AKTIV-DRY            Topic: NIAID

    DESCRIPTION (provided by applicant): The overarching goal of this project is to move a new, dry powder formulation of Hepatitis-B vaccine on its path to commercialization. In the Phase I SBIR we tested in vitro three Hep-B dry powder formulations of commercially available Shanvac-B and demonstrated powder stability and immunogenicity at temperatures ranging from -20 ?C through 65 oC. At these temp ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic

    SBC: CRESTONE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The alarming increase in incidence of infections caused by drug-resistant bacteria has created an urgent need for new antibacterial agents. We are developing a novel class of small molecule antibiotics ( TZUs ) targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. These agents exhibit broad-spectrum activity against Gram-positive bacteria, ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government